We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ASGN Inc | NYSE:ASGN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.14 | 0.15% | 94.16 | 94.63 | 93.0001 | 93.575 | 198,178 | 00:07:22 |
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
95-4023433
|
|
|
||||
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
|
|
||||
|
|
|
|
||||
26745 Malibu Hills Road, Calabasas, CA
|
91301
|
|
|
||||
(Address of principal executive offices)
|
(Zip Code)
|
|
|
||||
|
|
|
|
||||
(818) 878-7900
|
|
||||||
(Registrant’s telephone number, including area code)
|
|
||||||
|
|
|
|
|
|
Large accelerated filer
o
|
Accelerated filer
x
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2013
|
|
December 31, 2012
|
||||
ASSETS
|
|
|
|
||||
Current Assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
11,774
|
|
|
$
|
27,479
|
|
Accounts receivable, net of allowance of $3,165 and $3,970, respectively
|
257,196
|
|
|
243,003
|
|
||
Prepaid expenses
|
6,744
|
|
|
8,839
|
|
||
Deferred income tax assets
|
10,118
|
|
|
10,147
|
|
||
Other
|
9,528
|
|
|
4,289
|
|
||
Total current assets
|
295,360
|
|
|
293,757
|
|
||
|
|
|
|
||||
Property and equipment, net
|
27,742
|
|
|
26,862
|
|
||
Goodwill
|
497,580
|
|
|
498,356
|
|
||
Identifiable intangible assets, net
|
258,324
|
|
|
263,840
|
|
||
Other long-term assets
|
14,430
|
|
|
15,206
|
|
||
Total Assets
|
$
|
1,093,436
|
|
|
$
|
1,098,021
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
Current Liabilities:
|
|
|
|
||||
Current portion of long-term debt
|
$
|
10,000
|
|
|
$
|
10,000
|
|
Accounts payable
|
5,453
|
|
|
6,810
|
|
||
Accrued payroll and contract professional pay
|
62,045
|
|
|
59,962
|
|
||
Deferred compensation
|
5,150
|
|
|
10,000
|
|
||
Workers’ compensation and medical malpractice loss reserves
|
10,509
|
|
|
10,327
|
|
||
Income taxes payable
|
11,696
|
|
|
191
|
|
||
Current portion of accrued earn-outs
|
6,099
|
|
|
6,563
|
|
||
Other
|
17,947
|
|
|
14,874
|
|
||
Total current liabilities
|
128,899
|
|
|
118,727
|
|
||
|
|
|
|
||||
Deferred income tax liabilities
|
22,966
|
|
|
23,009
|
|
||
Long-term debt
|
373,588
|
|
|
416,588
|
|
||
Other long-term liabilities
|
6,200
|
|
|
6,974
|
|
||
Total liabilities
|
531,653
|
|
|
565,298
|
|
||
Commitments and Contingencies
|
|
|
|
|
|
||
Stockholders’ Equity:
|
|
|
|
||||
Preferred Stock, $0.01 par value, 1,000,000 shares authorized, no shares issued
|
—
|
|
|
—
|
|
||
Common Stock, $0.01 par value, 75,000,000 shares authorized, 53,212,419 and 52,960,570 issued and outstanding, respectively
|
532
|
|
|
530
|
|
||
Paid-in capital
|
477,348
|
|
|
471,711
|
|
||
Retained earnings
|
86,300
|
|
|
61,687
|
|
||
Accumulated other comprehensive loss
|
(2,397
|
)
|
|
(1,205
|
)
|
||
Total stockholders’ equity
|
561,783
|
|
|
532,723
|
|
||
Total Liabilities and Stockholders’ Equity
|
$
|
1,093,436
|
|
|
$
|
1,098,021
|
|
|
Three Months Ended
|
||||||
March 31,
|
|||||||
|
2013
|
|
2012
|
||||
Revenues
|
$
|
389,193
|
|
|
$
|
156,760
|
|
Cost of services
|
275,919
|
|
|
104,011
|
|
||
Gross profit
|
113,274
|
|
|
52,749
|
|
||
Selling, general and administrative expenses
|
84,161
|
|
|
42,745
|
|
||
Amortization of intangible assets
|
5,379
|
|
|
634
|
|
||
Operating income
|
23,734
|
|
|
9,370
|
|
||
Interest expense, net
|
(5,331
|
)
|
|
(701
|
)
|
||
Income before income taxes
|
18,403
|
|
|
8,669
|
|
||
Provision for income taxes
|
7,793
|
|
|
3,622
|
|
||
Income from continuing operations
|
10,610
|
|
|
5,047
|
|
||
Gain on sale of discontinued operations, net of income taxes
|
14,412
|
|
|
—
|
|
||
Income (loss) from discontinued operations, net of income taxes
|
(409
|
)
|
|
336
|
|
||
Net income
|
$
|
24,613
|
|
|
$
|
5,383
|
|
|
|
|
|
||||
Basic earnings per common share:
|
|
|
|
||||
Income from continuing operations
|
$
|
0.20
|
|
|
$
|
0.14
|
|
Income from discontinued operations
|
0.26
|
|
|
—
|
|
||
Net Income
|
$
|
0.46
|
|
|
$
|
0.14
|
|
|
|
|
|
||||
Diluted earnings per common share:
|
|
|
|
||||
Income from continuing operations
|
$
|
0.20
|
|
|
$
|
0.13
|
|
Income from discontinued operations
|
0.26
|
|
|
0.01
|
|
||
Net Income
|
$
|
0.46
|
|
|
$
|
0.14
|
|
|
|
|
|
||||
Number of shares and share equivalents used to calculate earnings per share:
|
|
|
|
||||
Basic
|
53,046
|
|
|
37,269
|
|
||
Diluted
|
54,036
|
|
|
38,154
|
|
||
|
|
|
|
||||
Reconciliation of net income to comprehensive income:
|
|
|
|
||||
Net income
|
$
|
24,613
|
|
|
$
|
5,383
|
|
Changes in fair value of derivatives, net of tax of $28 and $83 for the three months ended March 31, 2013 and 2012, respectively
(1)
|
67
|
|
|
—
|
|
||
Foreign currency translation adjustment
|
(1,259
|
)
|
|
1,097
|
|
||
Comprehensive income
|
$
|
23,421
|
|
|
$
|
6,480
|
|
|
Three Months Ended
|
||||||
March 31,
|
|||||||
|
2013
|
|
2012
|
||||
Cash Flows from Operating Activities:
|
|
|
|
||||
Net income
|
$
|
24,613
|
|
|
$
|
5,383
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
||||
Gain on sale of discontinued operations, net of income taxes
|
(14,412
|
)
|
|
—
|
|
||
Depreciation and amortization
|
7,244
|
|
|
2,063
|
|
||
Stock-based compensation
|
2,724
|
|
|
1,191
|
|
||
Gross excess tax benefits from stock-based compensation
|
(768
|
)
|
|
(913
|
)
|
||
Workers’ compensation and medical malpractice provision
|
1,288
|
|
|
930
|
|
||
Other
|
502
|
|
|
(127
|
)
|
||
Changes in operating assets and liabilities, net of effects of acquisitions and divestiture:
|
|
|
|
||||
Accounts receivable
|
(26,113
|
)
|
|
(7,729
|
)
|
||
Prepaid expenses and income taxes
|
2,151
|
|
|
1,560
|
|
||
Accounts payable
|
(1,089
|
)
|
|
1,306
|
|
||
Accrued payroll and contract professional pay
|
7,203
|
|
|
2,294
|
|
||
Deferred compensation
|
(4,850
|
)
|
|
(631
|
)
|
||
Other
|
5,082
|
|
|
1,646
|
|
||
Net cash provided by operating activities
|
3,575
|
|
|
6,973
|
|
||
Cash Flows from Investing Activities:
|
|
|
|
||||
Cash paid for property and equipment
|
(2,785
|
)
|
|
(2,119
|
)
|
||
Cash received for sale of discontinued operations, net
|
28,893
|
|
|
—
|
|
||
Other
|
(1,689
|
)
|
|
48
|
|
||
Net cash provided by (used in) investing activities
|
24,419
|
|
|
(2,071
|
)
|
||
Cash Flows from Financing Activities:
|
|
|
|
||||
Principal payments of long-term debt
|
(43,000
|
)
|
|
(6,250
|
)
|
||
Proceeds from stock transactions
|
2,443
|
|
|
2,183
|
|
||
Payments of employment taxes related to release of restricted stock awards
|
(3,611
|
)
|
|
(1,941
|
)
|
||
Gross excess tax benefits from stock-based compensation
|
768
|
|
|
913
|
|
||
Other
|
(20
|
)
|
|
(89
|
)
|
||
Net cash used in financing activities
|
(43,420
|
)
|
|
(5,184
|
)
|
||
Effect of exchange rate changes on cash and cash equivalents
|
(279
|
)
|
|
228
|
|
||
Net Decrease in Cash and Cash Equivalents
|
(15,705
|
)
|
|
(54
|
)
|
||
Cash and Cash Equivalents at Beginning of Year
|
27,479
|
|
|
17,739
|
|
||
Cash and Cash Equivalents at End of Period
|
$
|
11,774
|
|
|
$
|
17,685
|
|
|
|
|
|
||||
Supplemental Disclosure of Cash Flow Information:
|
|
|
|
||||
Cash paid for:
|
|
|
|
||||
Income taxes
|
$
|
3,861
|
|
|
$
|
1,018
|
|
Interest
|
$
|
4,673
|
|
|
$
|
630
|
|
|
|
|
|
||||
Supplemental Disclosure of Non-Cash Transactions:
|
|
|
|
||||
Acquisition of property and equipment through accounts payable
|
$
|
819
|
|
|
$
|
618
|
|
|
|
Apex
|
||
Current assets
|
|
$
|
169,844
|
|
Property and equipment
|
|
902
|
|
|
Goodwill
|
|
266,788
|
|
|
Identifiable intangible assets
|
|
251,555
|
|
|
Other
|
|
494
|
|
|
Total assets acquired
|
|
$
|
689,583
|
|
|
|
|
||
Current liabilities
|
|
$
|
77,905
|
|
Other
|
|
850
|
|
|
Total liabilities assumed
|
|
78,755
|
|
|
Total purchase price
|
|
$
|
610,828
|
|
|
|
|
Identifiable Intangible Asset Value
|
||
|
Useful life
|
|
Apex
|
||
Contractor relationships
|
5 years
|
|
$
|
10,589
|
|
Customer relationships
|
10 years
|
|
92,147
|
|
|
Non-compete agreements
|
7 years
|
|
2,076
|
|
|
Trademarks
|
indefinite
|
|
146,743
|
|
|
Total identifiable intangible assets acquired
|
|
|
$
|
251,555
|
|
Revenues
|
$
|
342,721
|
|
Operating income
|
$
|
13,464
|
|
Income from continuing operations
|
$
|
7,839
|
|
Net income
|
$
|
8,175
|
|
|
|
||
Basic earnings per share:
|
|
||
Income from continuing operations
|
$
|
0.15
|
|
Net income
|
$
|
0.16
|
|
|
|
||
Diluted earnings per share:
|
|
||
Income from continuing operations
|
$
|
0.15
|
|
Net income
|
$
|
0.16
|
|
|
|
||
Weighted average number of shares outstanding
|
51,574
|
|
|
Weighted average number of shares and dilutive shares outstanding
|
52,459
|
|
|
Three Months Ended
|
||||||
|
March 31,
|
||||||
|
2013
|
|
2012
|
||||
Revenues
|
$
|
6,432
|
|
|
$
|
10,318
|
|
Income (loss) before income taxes
|
$
|
(513
|
)
|
|
$
|
577
|
|
Provision (benefit) for income taxes
|
$
|
(104
|
)
|
|
$
|
241
|
|
Net income (loss)
|
$
|
(409
|
)
|
|
$
|
336
|
|
|
March 31,
2013 |
|
December 31, 2012
|
||||
Senior Secured Debt --
|
|
|
|
||||
$75 million revolving credit facility, due May 2017
|
$
|
—
|
|
|
$
|
—
|
|
$100 million term A loan facility, due May 2017
|
90,000
|
|
|
92,500
|
|
||
$365 million term B loan facility, due May 2019
|
293,588
|
|
|
334,088
|
|
||
|
$
|
383,588
|
|
|
$
|
426,588
|
|
Derivative designated as hedging instrument under ASC 815
|
|
|
|
|
|
||||
Balance Sheet Classification
|
|
March 31,
2013 |
|
December 31, 2012
|
|||||
Interest rate contracts
|
Other long-term assets
|
|
$
|
73
|
|
|
$
|
69
|
|
Interest rate contracts
|
Other liabilities
|
|
(327
|
)
|
|
(362
|
)
|
||
Interest rate contracts
|
Other long-term liabilities
|
|
—
|
|
|
(55
|
)
|
||
|
|
|
$
|
(254
|
)
|
|
$
|
(348
|
)
|
|
As of March 31, 2013
|
||||||||||||||
|
Fair Value Measurements Using
|
|
Total
|
||||||||||||
|
Quoted Prices in Active Markets for Identical Assets
|
|
Significant Other Observable Inputs
|
|
Significant Unobservable Inputs
|
|
|
||||||||
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
|
||||||||
Interest rate contracts
|
$
|
—
|
|
|
$
|
(254
|
)
|
|
$
|
—
|
|
|
$
|
(254
|
)
|
Contingent consideration to be paid in cash for the acquisitions
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(6,544
|
)
|
|
$
|
(6,544
|
)
|
|
|
|
|
|
|
|
|
||||||||
|
As of December 31, 2012
|
||||||||||||||
|
Fair Value Measurements Using
|
|
Total
|
||||||||||||
|
Quoted Prices in Active Markets for Identical Assets
|
|
Significant Other Observable Inputs
|
|
Significant Unobservable Inputs
|
|
|
||||||||
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
|
|||||||||
Interest rate contracts
|
$
|
—
|
|
|
$
|
(348
|
)
|
|
$
|
—
|
|
|
$
|
(348
|
)
|
Contingent consideration to be paid in cash for the acquisitions
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(7,577
|
)
|
|
$
|
(7,577
|
)
|
|
Three Months Ended
|
||||||
|
March 31,
|
||||||
|
2013
|
|
2012
|
||||
Contingent consideration for acquisitions
|
|
|
|
||||
Balance at beginning of period
|
$
|
(7,577
|
)
|
|
$
|
(9,856
|
)
|
Fair value adjustment
|
830
|
|
|
(32
|
)
|
||
Foreign currency translation adjustment
|
203
|
|
|
(203
|
)
|
||
Balance at end of period
|
$
|
(6,544
|
)
|
|
$
|
(10,091
|
)
|
|
Apex
|
|
Oxford
|
|
Life Sciences
|
|
Healthcare
|
|
Physician
|
|
Total
|
||||||||||||
Balance as of December 31, 2011
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Gross goodwill
|
$
|
—
|
|
|
$
|
149,483
|
|
|
$
|
27,668
|
|
|
$
|
122,230
|
|
|
$
|
51,570
|
|
|
$
|
350,951
|
|
Accumulated impairment loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(121,717
|
)
|
|
—
|
|
|
(121,717
|
)
|
||||||
|
—
|
|
|
149,483
|
|
|
27,668
|
|
|
513
|
|
|
51,570
|
|
|
229,234
|
|
||||||
Apex acquisition
|
266,788
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
266,788
|
|
||||||
Acquisition accounting
|
—
|
|
|
—
|
|
|
1,814
|
|
|
—
|
|
|
(9
|
)
|
|
1,805
|
|
||||||
Translation adjustment
|
—
|
|
|
—
|
|
|
529
|
|
|
—
|
|
|
—
|
|
|
529
|
|
||||||
Balance as of December 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Gross goodwill
|
266,788
|
|
|
149,483
|
|
|
30,011
|
|
|
122,230
|
|
|
51,561
|
|
|
620,073
|
|
||||||
Accumulated impairment loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(121,717
|
)
|
|
—
|
|
|
(121,717
|
)
|
||||||
|
266,788
|
|
|
149,483
|
|
|
30,011
|
|
|
513
|
|
|
51,561
|
|
|
498,356
|
|
||||||
Divestiture - gross goodwill
|
—
|
|
|
—
|
|
|
—
|
|
|
(121,717
|
)
|
|
—
|
|
|
(121,717
|
)
|
||||||
Divestiture - accumulated impairment loss
|
—
|
|
|
—
|
|
|
—
|
|
|
121,717
|
|
|
—
|
|
|
121,717
|
|
||||||
Translation adjustment
|
—
|
|
|
—
|
|
|
(776
|
)
|
|
—
|
|
|
—
|
|
|
(776
|
)
|
||||||
Balance as of March 31, 2013
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Gross goodwill
|
266,788
|
|
|
149,483
|
|
|
29,235
|
|
|
513
|
|
|
51,561
|
|
|
497,580
|
|
||||||
Accumulated impairment loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
$
|
266,788
|
|
|
$
|
149,483
|
|
|
$
|
29,235
|
|
|
$
|
513
|
|
|
$
|
51,561
|
|
|
$
|
497,580
|
|
|
|
|
March 31, 2013
|
|
December 31, 2012
|
||||||||||||||||||||
|
Estimated Useful Life
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
||||||||||||
Intangible assets subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Customer relations
|
3 months – 10 years
|
|
$
|
103,223
|
|
|
$
|
27,819
|
|
|
$
|
75,404
|
|
|
$
|
103,285
|
|
|
$
|
23,338
|
|
|
$
|
79,947
|
|
Contractor relations
|
2 - 7 years
|
|
37,848
|
|
|
28,466
|
|
|
9,382
|
|
|
37,871
|
|
|
27,754
|
|
|
10,117
|
|
||||||
Non-compete agreements
|
2 - 7 years
|
|
2,972
|
|
|
1,183
|
|
|
1,789
|
|
|
2,986
|
|
|
1,062
|
|
|
1,924
|
|
||||||
|
|
|
144,043
|
|
|
57,468
|
|
|
86,575
|
|
|
144,142
|
|
|
52,154
|
|
|
91,988
|
|
||||||
Intangible assets not subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Trademarks
|
|
|
171,749
|
|
|
—
|
|
|
171,749
|
|
|
171,852
|
|
|
—
|
|
|
171,852
|
|
||||||
Goodwill
|
|
|
497,580
|
|
|
—
|
|
|
497,580
|
|
|
498,356
|
|
|
—
|
|
|
498,356
|
|
||||||
Total
|
|
|
$
|
813,372
|
|
|
$
|
57,468
|
|
|
$
|
755,904
|
|
|
$
|
814,350
|
|
|
$
|
52,154
|
|
|
$
|
762,196
|
|
2013
|
$
|
15,588
|
|
2014
|
16,817
|
|
|
2015
|
14,300
|
|
|
2016
|
12,365
|
|
|
2017
|
8,993
|
|
|
Thereafter
|
18,512
|
|
|
|
$
|
86,575
|
|
|
Three Months Ended
|
||||
|
March 31,
|
||||
|
2013
|
|
2012
|
||
Weighted average number of common shares outstanding used to compute basic earnings per share
|
53,046
|
|
|
37,269
|
|
Dilutive effect of stock-based awards
|
990
|
|
|
885
|
|
Number of shares used to compute diluted earnings per share
|
54,036
|
|
|
38,154
|
|
|
Three Months Ended
|
||||
|
March 31,
|
||||
|
2013
|
|
2012
|
||
Anti-dilutive common share equivalents outstanding
|
77
|
|
|
710
|
|
|
Three Months Ended
|
||||||
|
March 31,
|
||||||
|
2013
|
|
2012
|
||||
Revenues:
|
|
|
|
||||
Apex
|
$
|
212,728
|
|
|
$
|
—
|
|
Oxford
|
95,262
|
|
|
78,759
|
|
||
Life Sciences
|
40,473
|
|
|
41,351
|
|
||
Physician
|
26,302
|
|
|
24,089
|
|
||
Healthcare
|
14,428
|
|
|
12,561
|
|
||
|
$
|
389,193
|
|
|
$
|
156,760
|
|
Gross Profit:
|
|
|
|
||||
Apex
|
$
|
55,619
|
|
|
$
|
—
|
|
Oxford
|
32,150
|
|
|
27,370
|
|
||
Life Sciences
|
13,384
|
|
|
13,839
|
|
||
Physician
|
7,483
|
|
|
7,499
|
|
||
Healthcare
|
4,638
|
|
|
4,041
|
|
||
|
$
|
113,274
|
|
|
$
|
52,749
|
|
Operating Income (Loss):
|
|
|
|
||||
Apex
|
$
|
10,079
|
|
|
$
|
—
|
|
Oxford
|
11,405
|
|
|
7,235
|
|
||
Life Sciences
|
692
|
|
|
2,308
|
|
||
Physician
|
2,154
|
|
|
1,078
|
|
||
Healthcare
|
(596
|
)
|
|
(1,251
|
)
|
||
|
$
|
23,734
|
|
|
$
|
9,370
|
|
|
Three Months Ended
|
||||||
|
March 31,
|
||||||
|
2013
|
|
2012
|
||||
Revenues:
|
|
|
|
||||
Domestic
|
$
|
368,797
|
|
|
$
|
137,444
|
|
Foreign
|
20,396
|
|
|
19,316
|
|
||
|
$
|
389,193
|
|
|
$
|
156,760
|
|
|
March 31,
2013 |
|
December 31, 2012
|
||||
Total Assets:
|
|
|
|
||||
Apex
|
$
|
647,463
|
|
|
$
|
642,594
|
|
Oxford
|
235,846
|
|
|
231,211
|
|
||
Life Sciences and Healthcare
|
127,431
|
|
|
139,601
|
|
||
Physician
|
82,696
|
|
|
84,615
|
|
||
|
$
|
1,093,436
|
|
|
$
|
1,098,021
|
|
|
Three Months Ended
|
||||||
|
March 31,
|
||||||
|
2013
|
|
2012
|
||||
Revenues
|
100.0
|
|
%
|
|
100.0
|
|
%
|
Cost of services
|
70.9
|
|
|
|
66.4
|
|
|
Gross profit
|
29.1
|
|
|
|
33.6
|
|
|
Selling, general and administrative expenses
|
21.6
|
|
|
|
27.3
|
|
|
Amortization
|
1.4
|
|
|
|
0.4
|
|
|
Operating income
|
6.1
|
|
|
|
5.9
|
|
|
Interest expense, net
|
(1.4
|
)
|
|
|
(0.4
|
)
|
|
Income before income taxes
|
4.7
|
|
|
|
5.5
|
|
|
Provision for income taxes
|
2.0
|
|
|
|
2.3
|
|
|
Income from continuing operations
|
2.7
|
|
|
|
3.2
|
|
|
Gain on sale of discontinued operations, net of income taxes
|
3.7
|
|
|
|
—
|
|
|
Income (loss) from discontinued operations, net of income taxes
|
(0.1
|
)
|
|
|
0.2
|
|
|
Net income
|
6.3
|
|
%
|
|
3.4
|
|
%
|
CHANGES IN RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2013 COMPARED WITH THE THREE MONTHS ENDED MARCH 31, 2012
|
|
Three Months Ended
|
|
Change
|
||||||||||||
March 31,
|
|||||||||||||||
|
2013
|
|
2012
|
|
$
|
|
%
|
||||||||
Apex
|
$
|
212,728
|
|
|
$
|
—
|
|
|
$
|
212,728
|
|
|
—
|
|
%
|
Oxford
|
95,262
|
|
|
78,759
|
|
|
16,503
|
|
|
21.0
|
|
%
|
|||
Life Sciences
|
40,473
|
|
|
41,351
|
|
|
(878
|
)
|
|
(2.1
|
)
|
%
|
|||
Physician
|
26,302
|
|
|
24,089
|
|
|
2,213
|
|
|
9.2
|
|
%
|
|||
Healthcare
|
14,428
|
|
|
12,561
|
|
|
1,867
|
|
|
14.9
|
|
%
|
|||
|
$
|
389,193
|
|
|
$
|
156,760
|
|
|
$
|
232,433
|
|
|
148.3
|
|
%
|
|
Three Months Ended
|
|||||||||||||
March 31,
|
||||||||||||||
|
2013
|
|
2012
|
|||||||||||
|
Gross Profit
|
|
Gross Margin
|
|
Gross Profit
|
|
Gross Margin
|
|||||||
Apex
|
$
|
55,619
|
|
|
26.1
|
%
|
|
$
|
—
|
|
|
—
|
|
%
|
Oxford
|
32,150
|
|
|
33.7
|
%
|
|
27,370
|
|
|
34.8
|
|
%
|
||
Life Sciences
|
13,384
|
|
|
33.1
|
%
|
|
13,839
|
|
|
33.5
|
|
%
|
||
Physician
|
7,483
|
|
|
28.5
|
%
|
|
7,499
|
|
|
31.1
|
|
%
|
||
Healthcare
|
4,638
|
|
|
32.1
|
%
|
|
4,041
|
|
|
32.2
|
|
%
|
||
|
$
|
113,274
|
|
|
29.1
|
%
|
|
$
|
52,749
|
|
|
33.6
|
|
%
|
|
|
|
|
|
|
|
|
|
|
|
ON ASSIGNMENT, INC.
|
|
|
|
|
Date: May 9, 2013
|
By:
|
/s/ Peter T. Dameris
|
|
|
Peter T. Dameris
|
|
|
Chief Executive Officer and President (Principal Executive Officer)
|
|
|
|
Date: May 9, 2013
|
By:
|
/s/ Edward L. Pierce
|
|
|
Edward L. Pierce
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
1 Year ASGN Chart |
1 Month ASGN Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions